

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO Box 1450 Alexandria, Virginia 22313-1450 www.unpto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/551,162	09/28/2005	Stan Gronthos	75090/JPW/JW	3174
	7590 08/26/201 UNHAM, LLP	EXAMINER		
30 Rockefeller Plaza 20th Floor NEW YORK, NY 10112			BELYAVSKYI, MICHAIL A	
			ART UNIT	PAPER NUMBER
			1644	
			MAIL DATE	DELIVERY MODE
			08/26/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Office Action Summary

Application No.	Applicant(s)	
10/551,162	GRONTHOS ET AL.	
Examiner	Art Unit	
Michail A. Belyavskyi	1644	

earned patent term adjustment.	See 37 CFR 1.704(b).

		Michail A. Belyavskyi	1644	
Davied fo	The MAILING DATE of this communication app	ears on the cover sheet with the o	correspondence ad	ldress
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DA naisons of time may be available under the provisions of 37 CFR 1.3 SIX (6) MONTH'S from the mailing date of this communication. 2) period for reply is specified above, the maximum statutory period we to reply with the set or estendied period for reply with by statute, reply received by the Cff called that the three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 6(a). In no event, however, may a reply be tir ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this c D (35 U.S.C. § 133).	
Status				
2a) <u></u> □	Responsive to communication(s) filed on 29 Jul This action is <b>FINAL</b> . 2b) This Since this application is in condition for allowan closed in accordance with the practice under E	action is non-final. ce except for formal matters, pro		e merits is
Disposit	ion of Claims			
5)□ 6)⊠ 7)□	Claim(s) <u>68-81</u> is/are pending in the application 4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed.  Claim(s) <u>68-81</u> is/are rejected.  Claim(s) is/are objected to.  Claim(s) are subject to restriction and/or	n from consideration.		
Applicat	ion Papers			
10)□	The specification is objected to by the Examiner The drawing(s) filed onis/are: a) acce Applicant may not request that any objection to the c Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Examiner.	epted or b) objected to by the drawing(s) be held in abeyance. Seen on is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 Cl	, ,
Priority (	under 35 U.S.C. § 119			
a)	Acknowledgment is made of a claim for foreign  All b   Some * c   None of:  1. Certified copies of the priority documents  2. Certified copies of the priority documents  3. Copies of the certified copies of the prior  application from the International Bureau  See the attached detailed Office action for a list of	s have been received. s have been received in Applicative documents have been received (PCT Rule 17.2(a)).	ion No ed in this National	Stage
Attachmen	nt(s)			
		_		

Attachment(s)	
1) Notice of References Cited (PTO-892)	4) Interview Summary (PTO-413)
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date
3) X Information Disclosure Statement(s) (FTO/SB/08)	Notice of Informal Patent Application
Paper No(s)/Mail Date 07/29/10.	6) Other:

Application/Control Number: 10/551,162 Page 2

Art Unit: 1644

## RESPONSE TO APPLICANT'S AMENDMENT

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 07/29/10 has been entered.

Claims 68-81 are pending.

Claims 68-81 read on an enriched cell population of mesenchymal precursor cells, wherein at least 30 % of the total cells are 3G5 positive cells.

- 2. The rejections under of claims 68-81 under 35 U.S.C. 102(b) as being anticipated by Simmons et al, and under 35 U.S.C. 102(e) as being anticipated by US Patent 7,122,178(IDS) or US Patent Application 2005/0281790 or WO 01/04268 and under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-13 of US Patent 7,122,178 are hereby withdrawn in view of the amendment to claim 68. However, this rejection will be re-introduced when the new matter (wherein such 365 cells are mesenchymal precursor cells wwhich coprise mesenchymal precursor cells capable of giving rise to CFU-f and wherein at least 30 % of the total cells of the population are positive for the marker 3G5) is deleted from claim 23.
- 3. The following is a quotation of the first paragraph of 35 U.S.C. 112:
  The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it portains, or with which it is most nearly connected, to make and use the same and shall ast forth the best made contemplated by the inventor of carrying out his inventor.
- 4. Claims 68-81 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a New Matter rejection.

Application/Control Number: 10/551,162

Art Unit: 1644

"wherein such 3G5 cells are mesenchymal precursor cells which comprise mesenchymal precursor cells capable of giving rise to CFU-f and wherein at least 30 % of the total cells of the population are positive for the marker 3G5" claimed in claime 68 represent a departure from the specification and the claims as originally filed. The passages pointed by the applicant do not provide a clear support for the claimed "wherein such 3G5 cells are mesenchymal precursor cells wwhich coprise mesenchymal precursor cells capable of giving rise to CFU-f and wherein at least 30 % of the total cells of the population are positive for the marker 3G5".

In particular, at page 13, lines 24-26 the Specification disclosed that in bone marrow 3G5 positive MPS constitute about 15% of MPC based on SRRO-1 bright colony forming cells. At page 16, lines 11-13 and at page 26, lines 13-16 the Specification disclosed that FACS analysis demonstrated that only a minor portion (14%) of a bone marrow clonogenic colonies expressed the 3G5 antigen (Fig. 4B).

It is noted that based on said teaching of the Specification the prior art rejections have been withdrawn.

- 5 No claim is allowed
- 6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michail Belyavskyi whose telephone number is 571/272-0840. The examiner can normally be reached Monday through Friday from 9:00 AM to 5:30 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla can be reached on 571/272-0735.

The fax number for the organization where this application or proceeding is assigned is 571/273-8300

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <a href="http://pair-direct.uspto.gov">http://pair-direct.uspto.gov</a>. Should you have questions on access to the Private PAIR system. contact the Electronic Business Center (EBC) at 866-217-917 (toll-free).

Application/Control Number: 10/551,162 Page 4

Art Unit: 1644

/Michail A Belyavskyi/ Primary Examiner, Art Unit 1644